News

Ophthalmology Times1h
LumiThera announces topline results from LIGHTSITE IIIB extension trial
The trial assessed the Valeda Light Delivery System in patients with dry (non-neovascular) age-related macular degeneration ...
Ophthalmology Times3h
Q&A: Anat Loewenstein, MD, and results of a consensus group on managing diabetic retinopathy
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Ophthalmology Times18h
Q&A: Christine Kay, MD, gives an investigator's perspective on the PRISM clinical trial
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Ophthalmology Times22h
Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops
NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action ...
Ophthalmology Times18h
ARVO 2025: Update on the LIGHTSITE III study in AMD
At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.